Sage Therapeutics, Inc. (SAGE): Kimi Iguchi , CFO, Secretary and Treasurer of Sage Therapeutics, Inc. sold 5,000 shares on Jul 12, 2016. The Insider selling transaction was reported by the company on Jul 14, 2016 to the Securities and Exchange Commission. The shares were sold at $49.55 per share for a total value of $247,750.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Kevin P Starr (director 10% owner) sold 850,000 shares at $31.25 per share price.On Apr 21, 2016, Stephen Kanes (Chief Medical Officer) sold 21,000 shares at $38.00 per share price.Also, On Jan 7, 2016, Kimi Iguchi (CFO) purchased 176 shares at $49.56 per share price.On Aug 4, 2015, Albert Robichaud (Chief Scientific Officer) sold 12,000 shares at $67.06 per share price.
Shares of SAGE Therapeutics Inc (SAGE) ended Wednesday, Jul 13, 2016 session in red amid volatile trading. The shares closed down -3.78 points or -8.18% at $42.43 with 30,48,800 shares getting traded. Post opening the session at $46.44, the shares hit an intraday low of $41.0798 and an intraday high of $46.71 and the price vacillated in this range throughout the day. The company has a market cap of $1,360 M and the number of outstanding shares has been calculated to be 3,20,63,547 shares. The 52-week high of SAGE Therapeutics Inc is $77.48 and the 52-week low is $26.2801.
Company has been under the radar of several Street Analysts.SAGE Therapeutics Inc is Initiated by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $56. The Rating was issued on Jun 23, 2016.SAGE Therapeutics Inc is Initiated by Chardan Capital Markets to Sell and the brokerage firm has set the Price Target at $18. The Rating was issued on May 24, 2016.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.